Company / Cash & Equivalents
Beta Bionics, Inc. Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$31.6M
FY2025
5-year range
$26.6M / $31.6M
FY2023-FY2025
Trend
+3.8%
vs FY2024
Sector context
#141 of 148
Health Care
What the data says
Among 148 Health Care companies, Beta Bionics, Inc. is in the bottom 5% for cash & equivalents. Improved from $27M to $32M over the past 2 years.
Based on SEC 10-K filings.
$32M in FY2025.
Improved from $27M to $32M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 148This company $31.6M Sector average $1.2B
▼
-97.3% below sector average
Key checks
Key Insights
- In FY2025, cash & equivalents increased 3.8% year-over-year.
- Ranks #141 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $31.6M | +3.8% |
| FY2024 | $30.4M | +14.6% |
| FY2023 | $26.6M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026